Pilot Study of High Dose ICE (Ifosfamide, Carboplatin, 
Etoposide) Chemotherapy and Autologous Bone Marrow 
Transplant (ABMT) with neo - Transduced Bone Marrow Stem 
Cells 
1 . Objectives 
1.1 To study the feasibility of obtaining bone marrow engraftment 
post-high dose chemotherapy with retrovirally-transduced 
hematopoietic stem cells bearing the neomycin resistance 
marker gene. 
1.2 To study the trafficking and survival times of reinfused neo - 
transduced bone marrow cells in the peripheral blood and bone 
marrow during marrow engraftment following high dose 
chemotherapy. 
1.3 To study the effects of chemotherapy on the neo -transduced 
stem cells and progeny following bone marrow engraftment. 
1.4 To study the effects of hematopoietic growth factor 
administration on the neo -transduced bone marrow and 
peripheral blood cells. 
2. Background 
Autologous Bone Marrow Transplantation in Metastatic Breast 
Cancer 
Stage IV breast cancer is currently incurable. The median survival 
for patients with metastatic disease is 18 - 24 months. Both 
hormonal and chemotherapy are considered palliative and have not 
been definitively shown to improve either disease-free (DFS) or 
overall survival (OS). 
Autologous Bone Marrow Transplantation (ABMT) following high dose 
chemotherapy has been the subject of intense investigation as a 
Recombinant DNA Research, Volume 16 
[91] 
